E Psychedelic Drug Stocks Category Is +6% Month-To-Date

TM Editors' Note: This article discusses penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.

41 psychedelic drug stocks trade on the various North American stock exchanges and so far this week 21 have gone up, 11 have gone down and 9 have had no change in price. 

Chris Thompson, President and Director of Equity Research at eResearch  Corporation, the new parent company of munKNEE.com, reports research has shown that the psychedelic drugs market:

  • is growing with a CAGR of 16.3% between 2020 and 2027 and
  • is expected to reach $10.7 billion by 2027 from $2.1 billion in 2019. 

The 41 stocks consist of:

  • 7 micro-cap stocks (Group #1) with an average market capitalization of $197M,
  • 2 small-cap stocks (Group #2) with an average market capitalization of $1.2B,
  • 32 nano-cap stocks (Group #3) with an average market capitalization of just $33M.

Below is the stock price performance for each Group for the 3 days ending April 28th and month-to-date shown in brackets:

The 7 stocks in Group #1:

  • have market capitalizations ranging from $104M to $315M and average $197M,
  • have advanced 6.2% so far this week (+20.1% so far in April) and
  • are constituents in the munKNEE Pure-Play Psychedelic Drug Stocks Index as their market capitalizations are more than $100M and less than $1B.

The performance of the Group #1 constituents so far this week are, in descending order (month-to-date in brackets), as follows :

1 2 3 4
View single page >> |


Visit  munKNEE.com and register to receive our free Market Intelligence ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.